联合药物治疗策略有效治疗三阴性乳腺癌。
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
机构信息
Biology Division, Indian Institute of Science Education and Research (IISER) Tirupati, Andhra Pradesh, India.
Biology Division, Indian Institute of Science Education and Research (IISER) Tirupati, Andhra Pradesh, India
出版信息
Biosci Rep. 2018 Jan 30;38(1). doi: 10.1042/BSR20171357. Print 2018 Feb 28.
Abstract
TNBC (Triple Negative Breast Cancer) is a subtype of breast cancer with an aggressive phenotype which shows high metastatic capability and poor prognosis. Owing to its intrinsic properties like heterogeneity, lack of hormonal receptors and aggressive phenotype leave chemotherapy as a mainstay for the treatment of TNBC. Various studies have demonstrated that chemotherapy alone or therapeutic drugs targeting TNBC pathways, epigenetic mechanisms and immunotherapy alone have not shown significant improvement in TNBC patients. On the other hand, a combination of therapeutic drugs or addition of chemotherapy with therapeutic drugs has shown substantial improvement in results and proven to be an effective strategy for TNBC treatment. This review sheds light on effective combinational drug strategies and current clinical trial status of various combinatorial drugs for the treatment of TNBC.
摘要
三阴性乳腺癌（Triple Negative Breast Cancer，TNBC）是一种侵袭性表型的乳腺癌亚型，具有较高的转移能力和较差的预后。由于其内在特性，如异质性、缺乏激素受体和侵袭性表型，使化疗成为治疗 TNBC 的主要手段。各种研究表明，单独化疗或针对 TNBC 途径、表观遗传机制和免疫疗法的治疗药物单独使用，并未显示对 TNBC 患者有显著改善。另一方面，治疗药物的联合使用或化疗与治疗药物的联合使用显示出显著的结果改善，并已被证明是治疗 TNBC 的有效策略。本综述阐明了有效的联合药物策略以及目前各种联合药物治疗 TNBC 的临床试验现状。
相似文献
1
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
Biosci Rep. 2018 Jan 30;38(1). doi: 10.1042/BSR20171357. Print 2018 Feb 28.
2
Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
Mini Rev Med Chem. 2024;24(4):431-439. doi: 10.2174/1389557523666230517152538.
3
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.
4
Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Oncology (Williston Park). 2020 May 13;34(5):176-182.
5
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
BMC Cancer. 2018 Nov 6;18(1):1074. doi: 10.1186/s12885-018-4979-0.
6
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Cancer Treat Rev. 2016 Nov;50:129-141. doi: 10.1016/j.ctrv.2016.09.004. Epub 2016 Sep 12.
7
A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
Cancer Biol Ther. 2015;16(5):678-83. doi: 10.1080/15384047.2015.1026481.
8
Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
Eur J Pharmacol. 2024 Jun 15;973:176568. doi: 10.1016/j.ejphar.2024.176568. Epub 2024 Apr 9.
9
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
World J Surg Oncol. 2014 Apr 15;12:95. doi: 10.1186/1477-7819-12-95.
10
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002022.
引用本文的文献
1
JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells.
Int J Mol Sci. 2025 Jun 26;26(13):6139. doi: 10.3390/ijms26136139.
2
Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models.
Int J Mol Sci. 2025 Jan 3;26(1):366. doi: 10.3390/ijms26010366.
3
Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis.
Front Oncol. 2024 Oct 14;14:1423924. doi: 10.3389/fonc.2024.1423924. eCollection 2024.
4
Secondary Transcriptomic Analysis of Triple-Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific Mechanistic Markers.
Cancers (Basel). 2024 Oct 2;16(19):3379. doi: 10.3390/cancers16193379.
5
VIBRANT: spectral profiling for single-cell drug responses.
Nat Methods. 2024 Mar;21(3):501-511. doi: 10.1038/s41592-024-02185-x. Epub 2024 Feb 19.
6
Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer.
Curr Issues Mol Biol. 2022 Nov 23;44(12):5848-5865. doi: 10.3390/cimb44120398.
7
β-Caryophyllene Counteracts Chemoresistance Induced by Cigarette Smoke in Triple-Negative Breast Cancer MDA-MB-468 Cells.
Biomedicines. 2022 Sep 12;10(9):2257. doi: 10.3390/biomedicines10092257.
8
Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
J Zhejiang Univ Sci B. 2022 Aug 15;23(8):617-624. doi: 10.1631/jzus.B2200113.
9
The role of epigenetic modifications in drug resistance and treatment of breast cancer.
Cell Mol Biol Lett. 2022 Jun 28;27(1):52. doi: 10.1186/s11658-022-00344-6.
10
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
BMC Cancer. 2022 Jun 8;22(1):627. doi: 10.1186/s12885-022-09690-2.
本文引用的文献
1
Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression of tumor suppressor genes and inhibits growth of triple-negative breast tumor.
Oncotarget. 2015 May 9;8(48):83457-83468. doi: 10.18632/oncotarget.4054. eCollection 2017 Oct 13.
2
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Cancer Res. 2017 Nov 15;77(22):6340-6352. doi: 10.1158/0008-5472.CAN-17-2210. Epub 2017 Sep 25.
3
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.
4
Oestrogen receptor negativity in breast cancer: a cause or consequence?
Biosci Rep. 2016 Dec 23;36(6). doi: 10.1042/BSR20160228. Print 2016 Dec.
5
Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
J Biol Chem. 2016 Nov 4;291(45):23756-23768. doi: 10.1074/jbc.M116.738666. Epub 2016 Sep 20.
6
Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Oncotarget. 2016 Sep 27;7(39):63189-63203. doi: 10.18632/oncotarget.11055.
7
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.
Oncogenesis. 2016 Aug 15;5(8):e255. doi: 10.1038/oncsis.2016.50.
8
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
Oncotarget. 2016 Sep 13;7(37):60712-60722. doi: 10.18632/oncotarget.10858.
9
Biology and Management of Patients With Triple-Negative Breast Cancer.
Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
10
Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value.
Mol Cell Oncol. 2015 May 26;3(1):e1038424. doi: 10.1080/23723556.2015.1038424. eCollection 2016 Jan.
Zotero 插件